Kalos Management, Inc. Acadia Pharmaceuticals Inc Transaction History

Kalos Management, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$13.01 - $27.22 $14,961 - $31,303	-1,150 Reduced 6.31%	17,075 $244,000
Q1 2022 Jun 21, 2022	SELL	$20.94 - $27.5 $30,656 - $40,260	-1,464 Reduced 7.44%	18,225 $441,000
Q4 2021 Feb 03, 2022	BUY	$16.79 - $27.09 $18,704 - $30,178	1,114 Added 6.0%	19,689 $340,000
Q3 2021 Nov 10, 2021	SELL	$15.78 - $24.77 $1,578 - $2,477	-100 Reduced 0.54%	18,575 $321,000
Q1 2021 May 13, 2021	SELL	$25.02 - $54.99 $6,880 - $15,122	-275 Reduced 1.45%	18,675 $460,000
Q4 2020 Feb 11, 2021	SELL	$41.04 - $56.79 $20,520 - $28,395	-500 Reduced 2.57%	18,950 $1.01 Million
Q3 2020 Nov 12, 2020	BUY	$36.42 - $57.0 $3,642 - $5,700	100 Added 0.52%	19,450 $812,000
Q2 2020 Aug 13, 2020	BUY	$39.26 - $52.73 $141,336 - $189,828	3,600 Added 22.86%	19,350 $935,000
Q1 2020 May 13, 2020	SELL	$31.65 - $46.87 $94,950 - $140,610	-3,000 Reduced 16.0%	15,750 $672,000
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $112,612 - $135,791	4,829 Added 34.69%	18,750 $501,000
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $99,105 - $167,812	-6,129 Reduced 30.57%	13,921 $373,000
Q4 2018 Feb 13, 2019	BUY	$14.32 - $22.92 $11,456 - $18,336	800 Added 4.16%	20,050 $420,000
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $18,242 - $30,534	1,400 Added 7.84%	19,250 $392,000
Q1 2018 May 14, 2018	SELL	$22.47 - $32.33 $17,976 - $25,864	-800 Reduced 4.29%	17,850 $416,000
Q4 2017 Feb 14, 2018	BUY	$26.84 - $39.14 $93,940 - $136,990	3,500 Added 23.1%	18,650 $558,000
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $446,773 - $581,305	15,150	15,150 $570,000

288

161M

723K

257K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.